Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
– Otenaproxesul demonstrated efficacy in acute pain clinical study conducted in the UK in 2019 TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the selection of a poster presentation of clinical data supporting otenaproxesul’s acute … [Read more…]
